Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Teijin ( (JP:3401) ).
Third-quarter FY2025 adjusted operating income fell ¥1.8 billion year-on-year to ¥23.8 billion as maintenance downtime, weaker materials mix, and the removal of aramid paper profits outweighed healthcare gains, with impairment charges tied to the temporarily idled U.S. carbon fiber plant. Management kept its full-year outlook for ¥25 billion in adjusted operating income and a ¥50 dividend intact while highlighting the planned December 2025 joint venture between Teijin Frontier and Asahi Kasei Advance to consolidate their textile operations and potentially sharpen competitiveness.
The most recent analyst rating on (JP:3401) stock is a Hold with a Yen1607.00 price target. To see the full list of analyst forecasts on Teijin stock, see the JP:3401 Stock Forecast page.
More about Teijin
Teijin Limited is a diversified Japanese conglomerate with core operations spanning advanced materials, healthcare technologies, and related services, with notable positions in aramid fibers, carbon composites, and home medical equipment across global industrial and medical markets.
Average Trading Volume: 934,131
Technical Sentiment Signal: Buy
Current Market Cap: Yen287.1B
Find detailed analytics on 3401 stock on TipRanks’ Stock Analysis page.